INMD
NASDAQInMode Ltd.
InMode Ltd. (INMD) is a Biotechnology: Electromedical & Electrotherapeutic Apparatus company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for INMD, including 1 earnings update, 1 press release or news item and 1 SEC filing. The most recent was published Oct 26, 2026.
INMD rankings
Financial highlights
Full financials- Revenue, FY2025
- $370.50M
- Revenue growth
- -6.2%
- Net income, FY2025
- $93.83M
- Net margin
- 25.3%
- Free cash flow, FY2025
- $84.28M
- Cash
- $302.54M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks34+200%
2026-05-102026-11-01
Mix690d
- SEC Filings3(50%)
- Other2(33%)
- Earnings1(17%)
Latest news
25 items- SECSEC Form 6-K filed by InMode Ltd.6-K - InMode Ltd. (0001742692) (Filer)
- PRSteel Partners Holdings L.P. Issues Open Letter to All InMode Stakeholders and Sets October 30, 2026 Expiration for Its $16.75 Per Share All-Cash OfferAfter More Than Three Months, the Company Has Refused to Engage on Steel’s Proposal Steel Believes Directors Breached Their Fiduciary Duties by Demanding Dismissal of Claims Against Them in Exchange for Diligence Steel’s Offer Delivers Certain Cash at a Premium or Shareholders Can Remain Invested in InMode Absent Meaningful Engagement, Steel Will Hold the Entrenched Board Accountable Steel Partners Holdings L.P. (together with its affiliates, "Steel"), a significant, long-standing shareholder of InMode Ltd. ("InMode" or the "Company") (NASDAQ:INMD), today issued an open letter to all InMode stakeholders. The full text of the letter is below. October 19, 2026 To All InMode Sta
- PRInMode to Report Third Quarter 2026 Financial Results on November 11, 2026, Expects Third Quarter Revenue of $91.8 Million to $92.0 Million, Reiterates FY 2026 Revenue Guidance Between $365M-$375MYOKNEAM, Israel, Oct. 13, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter of 2026 before the Nasdaq market opens on Wednesday, November 11, 2026.InMode is currently finalizing its financial results for the third quarter of 2026. While complete financial information and operating data are not yet available, set forth below are certain preliminary results for such period, which are unaudited and subject to the completion of InMode's quarter-end closing procedures, final adjustments and other developments that may arise between now and the time su
- SECSEC Form 6-K filed by InMode Ltd.6-K - InMode Ltd. (0001742692) (Filer)
- PRInMode Advances RF Microneedling Comfort with the Launch of Morpheus8 CoolIRVINE, Calif., Sept. 9, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, announces the launch of Morpheus8 Cool, the next evolution of its renowned Morpheus8 technology. Available exclusively on the new expandable Morpheus8MAX platform, Morpheus8 Cool advances radiofrequency (RF) microneedling with enhanced comfort, precision, control, and safety. Recognized as the world's #1 RF microneedling procedure, Morpheus8 is establishing a new industry standard with Morpheus8 Cool. The new handpiece and large-surface cooling tip feature game-changing Cool Comfort Technology,
- SECSEC Form 6-K filed by InMode Ltd.6-K - InMode Ltd. (0001742692) (Filer)
- INSIDERChief Financial Officer Itzkovich Moshe was granted 14,000 units of Ordinary Shares, increasing direct ownership by 57% to 38,430 units (SEC Form 4)4 - InMode Ltd. (0001742692) (Issuer)
- SECSEC Form 6-K filed by InMode Ltd.6-K - InMode Ltd. (0001742692) (Filer)
- PRInMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025YOKNEAM, Israel, Aug. 5, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter of 2026. Second Quarter 2026 Highlights:Quarterly GAAP revenues of $95.6 million, consistent with the second quarter of 2025.Quarterly revenues from consumables and service of $22.3 million, an increase of 13% compared to the second quarter of 2025.GAAP operating income of $12.3 million and *non-GAAP operating income of $16.0 million.Total cash position of $501.1 million as of June 30, 2026, including cash and cash equivalents, marketable securities and short-term bank deposi
- PREvery Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next OneNEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- American News Group News Commentary - The multi-billion-dollar medical aesthetics market is built on a handful of category-defining breakthroughs. The neuromodulator category that Botox® created. The hyaluronic-acid filler category. The biostimulator category. Each turned a novel way of treating the face into a franchise measured in billions, and the companies that own those categories, from AbbVie (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) to InMode (NASDAQ:INMD) and Anika Therapeutics (NASDAQ:ANIK), built enormous businesses around them. Now a wave of new demand is exposing the limits of the existing categories, and a preclinical company, Con
- SECSEC Form 6-K filed by InMode Ltd.6-K - InMode Ltd. (0001742692) (Filer)
- INSIDERDirector Kenneth Nadav was granted 2,000 units of Ordinary Shares, increasing direct ownership by 67% to 5,000 units (SEC Form 4)4 - InMode Ltd. (0001742692) (Issuer)
- INSIDERDirector Nass Shlomo was granted 2,000 units of Ordinary Shares (SEC Form 4)4 - InMode Ltd. (0001742692) (Issuer)
- INSIDERDirector Ron Hadar was granted 2,000 units of Ordinary Shares, increasing direct ownership by 3% to 60,270 units (SEC Form 4)4 - InMode Ltd. (0001742692) (Issuer)
- PRSteel Partners Urges InMode Shareholders to Vote AGAINST the Re-Election of Dr. Hadar Ron and AGAINST Extraordinary Special Committee Compensation at the July 30 Annual General MeetingBelieves Dr. Ron's Financial Ties and More Than Two Decades of Intertwined Business Interests with CEO Moshe Mizrahy Render Her Unable to Exert Independent Oversight Special Committee Did Not Accomplish Anything and Now Seeks Pay Exceeding the Company's Own Compensation Policy Shareholders Need to Send a Strong Message to the Board That They Must Engage with Potential Acquirers Other Than CEO Mizrahy Steel Partners Holdings L.P. (together with its affiliates, "Steel"), a significant, long-standing shareholder of InMode Ltd. ("InMode" or the "Company") (NASDAQ:INMD), today issued a letter to InMode shareholders urging them to vote AGAINST Proposal 1 and AGAINST Proposal 4 at the Compan
- SECSEC Form 6-K filed by InMode Ltd.6-K - InMode Ltd. (0001742692) (Filer)
- PRSteel Partners Holdings L.P. Issues Letter to InMode Ltd. Board of Directors Regarding the Company’s Persistent and Egregious Governance FailuresQuestions Whether Management is Steering Reported Results to Fit the CEO’s Lowball Bid Demands the Group Led by CEO Moshe Mizrahy Cure Its Disclosure Deficiencies Calls on the Board to Reschedule the Annual General Meeting to Allow Shareholders to Review Full Record and Bring Their Own Resolutions Steel Partners Holdings L.P. (together with its affiliates, "Steel"), a significant, long-standing shareholder of InMode Ltd. ("InMode" or the "Company") (NASDAQ:INMD), today issued a letter to the Board of Directors (the "Board") of the Company. The full text of the letter is below. July 16, 2026 VIA ELECTRONIC MAIL InMode Ltd. Tavor Building, Sha’ar Yokneam P.O. Box 533 Yokneam 20692
- SECSEC Form 6-K filed by InMode Ltd.6-K - InMode Ltd. (0001742692) (Filer)
- PRInMode to Report Second Quarter 2026 Financial Results on August 5, 2026, Expects Q2 Revenue Between $95.2M-$95.4M, Reiterates FY 2026 Revenue Guidance Between $365M-$375MYOKNEAM, Israel, July 13, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the second quarter of 2026 before the Nasdaq market opens on Wednesday, August 5, 2026. InMode is currently finalizing its financial results for the second quarter of 2026. While complete financial information and operating data are not yet available, set forth below are certain preliminary results such period, subject to final adjustments and other developments that may arise between now and the time such financial results a
- PRInMode Confirms Receipt of Unsolicited ProposalYOKNEAM, Israel, July 10, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) (the "Company") confirmed that its Board of Directors (the "Board") has received the unsolicited letter and acquisition proposal from Steel Partners Holdings L.P. dated July 9, 2026. The Special Committee comprised solely of the independent directors of the Board (the "Special Committee"), together with its legal and financial advisors, will carefully review the proposal consistent with its fiduciary duties.The Special Committee remains committed to acting in the best interests of all shareholders. The Special Committee does not intend to comment further at this time.About InMode Ltd.The Company is a leading global prov
- SECSEC Form 6-K filed by InMode Ltd.6-K - InMode Ltd. (0001742692) (Filer)
- PRSteel Partners Offers to Acquire InMode for $16.75 Per Share in CashSuperior Proposal Exceeds Conflicted CEO-Led $16.20 Insider Bid and Provides Optional Shareholder Rollover Demands the Board Take Immediate Action to Remove Incapable and Conflicted CEO Calls on Board to Form a Truly Independent Special Committee and Retain an Independent Investment Bank to Immediately Engage with Steel around Its Superior Offer Steel Partners Holdings L.P. (together with its affiliates, "Steel"), a significant, long-standing shareholder of InMode Ltd. ("InMode" or the "Company") (NASDAQ:INMD), today issued a letter to the Board of Directors (the "Board") of the Company, offering to acquire 100% of the shares of InMode for $16.75 per share in cash. The full text of th
- PRDOMA PERPETUAL CAPITAL MANAGEMENT STRONGLY OPPOSES INMODE BUYOUT AS PROPOSED; PLANS TO VOTE AGAINST DEALDOMA ASSERTS THAT THE $16.20 PER SHARE OFFER MATERIALLY UNDERVALUES INMODE AND ITS LONG-TERM POTENTIALDOMA BELIEVES THE BID EXPLOITS THE DEPRESSED VALUATIONS CREATED BY YEARS OF CEO-LED UNDERPERFORMANCEDOMA EXPLICITLY REJECTS THE CURRENT TERMS AND URGES THE BOARD TO UPLHOLD ITS FIDUCIARY DUTIESMIAMI, June 26, 2026 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE:INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board"). The letter can be downloaded hereThe full text of the letter follows:June 26,
- SECSEC Form 6-K filed by InMode Ltd.6-K - InMode Ltd. (0001742692) (Filer)
- PRThe Aesthetics Giants Just Confirmed “Ozempic Face” Is Real — and a Newly Public Regenerative Player Wants to Compete for ItIssued on behalf of Conexeu Sciences Inc. With Galderma now presenting clinical data on treating medication-driven facial volume loss, the GLP-1 aesthetics category has gone mainstream — and Conexeu Sciences Inc. (NASDAQ:CNXU) is positioning its regenerative CXU™ platform to compete for it. NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Biotech Insider — In emerging medical markets, the most telling signal is not the small company making the bold claim — it is the giant quietly proving the claim is real. That is exactly what has happened in aesthetics. Galderma, the pure-play dermatology leader behind Sculptra and Restylane, has been presenting interim clinical data demonstrating that i
INMD FAQ
11 questionsWhat does InMode Ltd. do?
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction...What is the latest news on INMD?
In the last 30 days Quantisnow tracked 3 wire items for INMD: 1 earnings update, 1 press release or news item and 1 SEC filing. The most recent was published on October 26, 2026.What is INMD revenue?
InMode Ltd. (INMD) reported $370.50M of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 6.2% from the year before.Is INMD profitable?
Yes. InMode Ltd. earned $93.83M in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 25.3%.How much cash and debt does INMD have?
InMode Ltd. reported $302.54M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does INMD stock trade?
InMode Ltd. (INMD) is listed on NASDAQ.What sector and industry is INMD in?
InMode Ltd. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did InMode Ltd. go public?
InMode Ltd. (INMD) completed its IPO in 2019.What are analysts saying about INMD?
Across the last 8 analyst actions on InMode Ltd., there were 0 upgrades and 6 downgrades. The most recent action was from BTIG Research: Neutral on 2025-04-29. Recent price targets range from $16.00 to $40.00.What companies are similar to INMD?
Notable peers in the same industry include MDT (Medtronic plc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation), AXGN (Axogen Inc.), TMDX (TransMedics Group Inc.). Compare INMD side-by-side with any of them on Quantisnow.How can I track INMD on Quantisnow?
Quantisnow aggregates InMode Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INMD to receive live email and push alerts on every new disclosure.